South San Francisco, United States
Vaxart, Inc., established in 2004, is at the forefront of a revolutionary shift in vaccine delivery, evidenced by their compelling slogan: "The pill that moves the needle." Operating in the Biotechnology, Health Care, and Medical Devices industries, this United States-based company is pioneering the development of oral vaccine pills.
Vaxart's groundbreaking approach seeks to transform traditional vaccine administration by developing pills targeting mucosal areas—the initial entry points of pathogens such as the nose, mouth, and gut. This methodology is designed to provoke robust IgA and T-cell responses, presenting a potentially more effective solution than intramuscular injections. Notably, Vaxart is the only company globally advancing to Phase II trials with a COVID-19 vaccine pill, alongside their ongoing progress with a Norovirus vaccine.
Already having secured a $40.00M post-IPO equity investment as of 01 June 2024, Vaxart presents a unique opportunity for investors looking to support transformative advancements in vaccine technology.
